Financial Ratios Shenyang Xingqi Pharmaceutical Co.,Ltd.
Equities
300573
CNE100002DV1
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
51.36 CNY | -3.26% |
|
-5.29% | +3.04% |
05-30 | Xingqi Pharmaceutical Says No Adverse Effects Seen in Phase 1 Eye Drops Trial | MT |
05-26 | Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 850 million in funding | CI |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 7.25 | 11.32 | 8.33 | 8.53 | 12.3 | |||||
Return on Total Capital | 9.16 | 13.47 | 9.56 | 9.74 | 14.27 | |||||
Return On Equity % | 14.73 | 20.52 | 14.62 | 14.81 | 20.59 | |||||
Return on Common Equity | 14.07 | 19.21 | 14.62 | 14.81 | 20.59 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 72.72 | 77.72 | 78.39 | 76.81 | 78.16 | |||||
SG&A Margin | 46.66 | 44.41 | 47.64 | 47 | 45.06 | |||||
EBITDA Margin % | 21.82 | 28.88 | 23.64 | 23.02 | 25.72 | |||||
EBITA Margin % | 15.39 | 23.43 | 18.54 | 17.81 | 21.38 | |||||
EBIT Margin % | 15.31 | 23.38 | 18.5 | 17.71 | 21.02 | |||||
Income From Continuing Operations Margin % | 13.57 | 20.34 | 16.94 | 16.36 | 17.4 | |||||
Net Income Margin % | 12.77 | 18.94 | 16.94 | 16.36 | 17.4 | |||||
Net Avail. For Common Margin % | 12.77 | 18.94 | 16.94 | 16.36 | 17.4 | |||||
Normalized Net Income Margin | 8.2 | 13.02 | 11.96 | 11.3 | 13.06 | |||||
Levered Free Cash Flow Margin | -2.42 | 12.38 | -10.66 | -1.42 | 10.7 | |||||
Unlevered Free Cash Flow Margin | -1.88 | 12.75 | -10.62 | -1.36 | 10.88 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.76 | 0.78 | 0.72 | 0.77 | 0.94 | |||||
Fixed Assets Turnover | 1.37 | 1.91 | 2.01 | 1.91 | 2.12 | |||||
Receivables Turnover (Average Receivables) | 4.73 | 6.23 | 6.71 | 6.44 | 7.26 | |||||
Inventory Turnover (Average Inventory) | 2.54 | 2.85 | 2.52 | 2.64 | 2.93 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.38 | 3.69 | 5.68 | 3.48 | 1.8 | |||||
Quick Ratio | 0.93 | 3.23 | 4.69 | 2.83 | 1.41 | |||||
Operating Cash Flow to Current Liabilities | 0.57 | 1.15 | 1.88 | 1.22 | 0.9 | |||||
Days Sales Outstanding (Average Receivables) | 77.31 | 58.59 | 54.39 | 56.67 | 50.42 | |||||
Days Outstanding Inventory (Average Inventory) | 144.33 | 128.02 | 145.01 | 138.5 | 124.85 | |||||
Average Days Payable Outstanding | 34.44 | 14.41 | 19.93 | 19.08 | 14.61 | |||||
Cash Conversion Cycle (Average Days) | 187.2 | 172.2 | 179.47 | 176.09 | 160.65 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 11.53 | 8.28 | 0.89 | 4.68 | 13.51 | |||||
Total Debt / Total Capital | 10.34 | 7.64 | 0.88 | 4.47 | 11.91 | |||||
LT Debt/Equity | - | 0.53 | 0.43 | 0.13 | 0.56 | |||||
Long-Term Debt / Total Capital | - | 0.49 | 0.43 | 0.13 | 0.49 | |||||
Total Liabilities / Total Assets | 28.13 | 20.3 | 12.94 | 16.5 | 25.12 | |||||
EBIT / Interest Expense | 17.76 | 40.11 | 246.62 | 180.77 | 71.49 | |||||
EBITDA / Interest Expense | 25.31 | 51.23 | 324.07 | 240.77 | 88.98 | |||||
(EBITDA - Capex) / Interest Expense | 7.09 | 35.36 | 4.88 | 58.59 | 54.2 | |||||
Total Debt / EBITDA | 0.53 | 0.36 | 0.05 | 0.23 | 0.42 | |||||
Net Debt / EBITDA | 0.28 | -1.87 | -1.65 | -1.16 | -0.3 | |||||
Total Debt / (EBITDA - Capex) | 1.9 | 0.53 | 3.02 | 0.94 | 0.7 | |||||
Net Debt / (EBITDA - Capex) | 1.02 | -2.71 | -109.57 | -4.76 | -0.5 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 26.96 | 49.26 | 21.59 | 17.42 | 32.42 | |||||
Gross Profit, 1 Yr. Growth % | 26.7 | 59.52 | 22.64 | 15.05 | 34.74 | |||||
EBITDA, 1 Yr. Growth % | 92.51 | 88.34 | -0.7 | 13.64 | 46.88 | |||||
EBITA, 1 Yr. Growth % | 176.27 | 112.54 | -4.07 | 11.91 | 57.45 | |||||
EBIT, 1 Yr. Growth % | 181.2 | 114.37 | -3.79 | 12.43 | 57.13 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 216.7 | 123.74 | 1.23 | 13.39 | 40.84 | |||||
Net Income, 1 Yr. Growth % | 145.11 | 121.31 | 8.72 | 13.39 | 40.84 | |||||
Normalized Net Income, 1 Yr. Growth % | 111.07 | 128.1 | 11.73 | 20.23 | 53 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 140 | 120.18 | 1.27 | 12.2 | 39.86 | |||||
Accounts Receivable, 1 Yr. Growth % | 21.35 | 7.83 | 14.27 | 29.31 | 10.25 | |||||
Inventory, 1 Yr. Growth % | -14.47 | 35.17 | 32.43 | 11.25 | 12.92 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 11.31 | 3.92 | 26.86 | 20.32 | 18.49 | |||||
Total Assets, 1 Yr. Growth % | 13.3 | 74.68 | 5.7 | 13.51 | 5.13 | |||||
Tangible Book Value, 1 Yr. Growth % | 20.87 | 100.75 | 15.36 | 5.7 | -9.5 | |||||
Common Equity, 1 Yr. Growth % | 20 | 97.09 | 15.46 | 8.86 | -5.73 | |||||
Cash From Operations, 1 Yr. Growth % | 64.9 | 151.28 | -6.74 | 10.94 | 31.3 | |||||
Capital Expenditures, 1 Yr. Growth % | 54.56 | -12.11 | 214.79 | -12.45 | -24.15 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -270.35 | -1.12K | -204.68 | -80.03 | -1.02K | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -203.13 | -1.59K | -201.24 | -80.78 | -1.08K | |||||
Dividend Per Share, 1 Yr. Growth % | 99.78 | 160.04 | 130.73 | 245.37 | -43.25 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 26.38 | 37.66 | 34.72 | 19.49 | 24.7 | |||||
Gross Profit, 2 Yr. CAGR % | 27.16 | 42.17 | 39.87 | 18.78 | 24.51 | |||||
EBITDA, 2 Yr. CAGR % | 79.35 | 95.02 | 36.92 | 6.54 | 29.68 | |||||
EBITA, 2 Yr. CAGR % | 201.46 | 150.59 | 43 | 4.01 | 33.38 | |||||
EBIT, 2 Yr. CAGR % | 211.46 | 153.17 | 43.61 | 4 | 32.91 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 222.1 | 166.19 | 50.5 | 7.14 | 26.37 | |||||
Net Income, 2 Yr. CAGR % | 153.8 | 132.9 | 55.12 | 11.03 | 26.37 | |||||
Normalized Net Income, 2 Yr. CAGR % | 143.94 | 123.6 | 59.64 | 11.36 | 35.63 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 151.96 | 129.85 | 49.4 | 6.55 | 25.33 | |||||
Accounts Receivable, 2 Yr. CAGR % | 21.77 | 14.39 | 11 | 21.56 | 19.4 | |||||
Inventory, 2 Yr. CAGR % | 10.14 | 7.52 | 33.79 | 21.38 | 12.08 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 11.45 | 7.55 | 14.82 | 23.55 | 19.4 | |||||
Total Assets, 2 Yr. CAGR % | 16.75 | 40.68 | 35.88 | 9.53 | 9.24 | |||||
Tangible Book Value, 2 Yr. CAGR % | 12.3 | 55.77 | 52.18 | 10.43 | -2.19 | |||||
Common Equity, 2 Yr. CAGR % | 11.83 | 53.78 | 50.85 | 12.11 | 1.31 | |||||
Cash From Operations, 2 Yr. CAGR % | 66.61 | 103.56 | 53.08 | 1.71 | 20.69 | |||||
Capital Expenditures, 2 Yr. CAGR % | 54.54 | 16.55 | 66.34 | 66.01 | -18.51 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -12.82 | 260.52 | 226.33 | -59.54 | 41.16 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -26.28 | 222.76 | 288.21 | -61 | 42.77 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | 127.93 | 144.95 | 182.29 | 40 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 24.14 | 33.58 | 32.08 | 28.68 | 23.65 | |||||
Gross Profit, 3 Yr. CAGR % | 23.68 | 37.15 | 35.34 | 31.05 | 23.88 | |||||
EBITDA, 3 Yr. CAGR % | 22.52 | 85.22 | 55.85 | 28.93 | 18.87 | |||||
EBITA, 3 Yr. CAGR % | 32.87 | 174.38 | 82.13 | 32.12 | 19.81 | |||||
EBIT, 3 Yr. CAGR % | 33.37 | 180.68 | 83.38 | 32.36 | 19.34 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 34.47 | 185.26 | 92.86 | 36.95 | 17.37 | |||||
Net Income, 3 Yr. CAGR % | 30.66 | 142.47 | 80.67 | 39.73 | 20.19 | |||||
Normalized Net Income, 3 Yr. CAGR % | 27.99 | 141.57 | 77.44 | 41.42 | 23.8 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 30.13 | 140.87 | 74.96 | 35.76 | 16.7 | |||||
Accounts Receivable, 3 Yr. CAGR % | 16.29 | 16.93 | 14.35 | 16.8 | 17.66 | |||||
Inventory, 3 Yr. CAGR % | 7.6 | 17.92 | 15.25 | 25.81 | 18.49 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 7.01 | 8.88 | 13.64 | 16.62 | 21.84 | |||||
Total Assets, 3 Yr. CAGR % | 12.6 | 33.53 | 27.89 | 27.97 | 8.05 | |||||
Tangible Book Value, 3 Yr. CAGR % | 7.75 | 36.29 | 40.93 | 34.77 | 3.34 | |||||
Common Equity, 3 Yr. CAGR % | 7.42 | 35.08 | 39.77 | 35.31 | 5.82 | |||||
Cash From Operations, 3 Yr. CAGR % | 55.17 | 91.06 | 56.92 | 37.5 | 10.75 | |||||
Capital Expenditures, 3 Yr. CAGR % | 54.56 | 28.04 | 62.31 | 34.3 | 27.86 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 79.8 | 79.66 | 138.73 | 18.52 | 17.75 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 135.76 | 76.41 | 119.3 | 31.32 | 17.29 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0 | 37.51 | 128.86 | 174.67 | 65.37 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 19.1 | 24.83 | 28.27 | 27.76 | 29.08 | |||||
Gross Profit, 5 Yr. CAGR % | 20.07 | 25.75 | 29.92 | 29.48 | 30.9 | |||||
EBITDA, 5 Yr. CAGR % | 16.06 | 25.37 | 29.32 | 48.54 | 44.97 | |||||
EBITA, 5 Yr. CAGR % | 25.15 | 32.69 | 38.69 | 86.25 | 61.04 | |||||
EBIT, 5 Yr. CAGR % | 25.59 | 32.98 | 39.07 | 88.69 | 61.23 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 33.57 | 30.96 | 40.66 | 92.81 | 62.86 | |||||
Net Income, 5 Yr. CAGR % | 31.97 | 29.11 | 39.94 | 77.41 | 56.6 | |||||
Normalized Net Income, 5 Yr. CAGR % | 33.17 | 31.96 | 40.88 | 77.22 | 56.82 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 23.9 | 21.44 | 37.52 | 73.85 | 53.08 | |||||
Accounts Receivable, 5 Yr. CAGR % | 13.8 | 11.92 | 14.15 | 18.76 | 16.34 | |||||
Inventory, 5 Yr. CAGR % | 12.04 | 13.93 | 17.4 | 19.29 | 13.97 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 2 | 4.36 | 10.07 | 14.52 | 15.91 | |||||
Total Assets, 5 Yr. CAGR % | 8.21 | 18.52 | 21.39 | 23.36 | 20.08 | |||||
Tangible Book Value, 5 Yr. CAGR % | 12.6 | 21.61 | 23.7 | 25.29 | 21.78 | |||||
Common Equity, 5 Yr. CAGR % | 11.84 | 20.88 | 23.04 | 25.37 | 22.89 | |||||
Cash From Operations, 5 Yr. CAGR % | 41.63 | 61.29 | 54.33 | 48.48 | 41.28 | |||||
Capital Expenditures, 5 Yr. CAGR % | 87.34 | 92.24 | 59.17 | 42.05 | 23.21 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -9.34 | 151.88 | 115.45 | -1.04 | 84.23 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -17.88 | 108.34 | 166.34 | -3.54 | 75.83 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | 39.03 | 43.1 | 83.35 | 88.02 |
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition